促进公平和及时获得个性化肿瘤治疗：中东和非洲

Summary Highlights from a Multi-StakeholderPanel Discussion at the 13th Annual EmiratesOncology Conference in November 2025 SUMMARY Table of Contents Panelists1Introduction2Background2Highlights from the panel discussion3Barriers to oncology therapy access across regions3Ongoing initiatives and solutions to improve access4A call-to-action6References7About the Institute8 REFERENCING THIS REPORT Please use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Advancing Equitable and Timely Access to Personalized Oncology Therapies:Middle East and Africa. March 2026. ©2026 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system,without express written consent of IQVIA and the IQVIA Institute. Panelists EXTERNAL SPEAKERS MODERATOR H.E. DR. MOUZA BIN HAMROURAL AMERIBreast Surgeon,Chief of Breast Care Center,Tawam Hospital/SEHA MURRAY AITKENExecutive Director,IQVIA Institute for HumanData Science DR. KHALED ABDEL-AZIZ KAMAL Consultant of Clinical Oncologyat Ain Shams University,Executive Director of the PresidentialInitiative for Cancer Early Detectionand Management DR. MOHAMMAD AL NAHEDH Director,Pharmaceutical Care Division,Clinical Pharmacy Consultant,Hematology/Oncology,King Faisal Specialist Hospital andResearch Center DR. JACQUES SNYMAN Director and owner of ForteResearch Co. (Pty) Ltd,Consultant for PharmacologyResearch and HTA The views of speakers do not necessarily represent those of their organizations. Introduction The IQVIA Institute for Human Data Science convenedan in-person and virtual multi-stakeholder symposiumat the 13th Annual Emirates Oncology Conference in AbuDhabi, UAE, on November 14, 2025. The panel discussion,Advancing Equitable and Timely Access to PersonalizedOncology Therapies: Middle East and Africa, coveredthe challenges and opportunities in accessing precisiononcology therapies across various regions. Participantsrepresented Egypt, Saudi Arabia, South Africa, and theUAE. Building on the IQVIA Institute’s published report,Oncology Therapy Access in the Era of PersonalizedMedicine: Trends in regulatory and reimbursementfor select countries in the Middle East and Africa, the aim of this session was to further the ongoingdiscussion about timely access to precisiononcology therapies. The panel was comprised of a broad range ofstakeholders, including oncology clinicians, policyleaders, and ex-payers. This summary provides highlights from the discussion. The symposium was organized by the IQVIA Institutefor Human Data Science as a public service with fundingfrom AbbVie, and was intended to continue the timelyconversation and propose a call to action for equitablepatient access to precision oncology therapies. Background Precision oncology - an approach that tailors therapeuticinterventions to an individual’s unique molecular profile- has transformed oncology care, ushering in a new waveof therapies. Despite these advancements, unequalaffordability and access continue to drive geographicdisparities. Research from the IQVIA Institute and othershas found that the availability and use of oncologytherapies differ drastically across various geographies,leading to disparities in patient outcomes.1–4Thesymposium opened with an overview of the researchfindings from the report published by IQVIA Institutein August 2025 as an introduction to the themes of thepanel discussion. quality of life.4However, despite notable progressin regulatory approvals and reimbursement,significant gaps remain in the registration and publicreimbursement of novel active substances (NAS) inthese regions. Systemic factors including variations in moleculeregistration process and timelines, variations inhealth technology assessment (HTA) frameworks,country-level disease prioritization, healthcare budgetand infrastructure, and manufacturer market entrystrategies continue to shape oncology therapy accessoutcomes. The presence and capacity for use ofcompanion diagnostics, essential for precision medicine,remain limited in many regions, constraining the uptakeof innovative therapies. However, while gaps remain,countries assessed in the report — Algeria, Egypt, SaudiArabia, South Africa, and the UAE — are striving to closethe gap through ongoing government led initiatives,including the Saudi VISION 2030, Emirati GenomeProgram, local manufacturing initiatives in Algeria,healthcare reform in Egypt, and HTA harmonizationtransformation in South Africa. The findings highlighted that landscape of oncologytherapy access across select countries in the Middle Eastand Africa is marked by rapid scientific advancementand persistent disparities. Precision oncology, drivenby molecular profiling and targeted therapies such asantibody-